يعرض 21 - 40 نتائج من 25,187 نتيجة بحث عن '(((( 50 nn decrease ) OR ( 5 non decrease ))) OR ( 50 ((we decrease) OR (a decrease)) ))', وقت الاستعلام: 2.04s تنقيح النتائج
  1. 21
  2. 22
  3. 23
  4. 24
  5. 25
  6. 26
  7. 27

    Data_Sheet_5_Decreased default mode network functional connectivity with visual processing regions as potential biomarkers for delayed neurocognitive recovery: A resting-state fMRI... حسب Zhaoshun Jiang (7478243)

    منشور في 2023
    "…</p>Results<p>We found significantly decreased DMN connectivity with the brain regions involved in visual processing in DNR patients than in non-DNR patients. …"
  8. 28
  9. 29
  10. 30
  11. 31
  12. 32
  13. 33
  14. 34
  15. 35
  16. 36

    The decrease or inhibition of Hsp90 induced REST degradation. حسب Raúl Orozco-Díaz (7067624)

    منشور في 2019
    "…<p>(A) Effect of Hsp90α ASO on cell viability. Differentiated SH-SY5Y cells were transfected with different concentrations of Hsp90α ASO. …"
  17. 37

    Global Land Use Change Impacts on Soil Nitrogen Availability and Environmental Losses حسب Jing Wang (6206297)

    منشور في 2025
    "…However, how global land use changes impact soil N supply and potential N loss remains elusive. By compiling a global data set of 1,782 paired observations from 185 publications, we show that land use conversion from natural to managed ecosystems significantly reduced NNM by 7.5% (−11.5, −2.8%) and increased NN by 150% (86, 194%), indicating decreasing N availability while increasing potential N loss through denitrification and nitrate leaching. …"
  18. 38

    Data_Sheet_1_Perceptual Priming Can Increase or Decrease With Aging.PDF حسب Kalathupiriyan A. Zhivago (9659504)

    منشور في 2020
    "…To measure implicit perceptual memory, we used a classic perceptual priming paradigm. Participants had to report the shape of a visual search pop-out target whose color or position was varied randomly across trials. …"
  19. 39
  20. 40

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc حسب Lei Wang (6656)

    منشور في 2025
    "…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …"